The antitussive effect of dextromethorphan in relation to CYP2D6 activity

British Journal of Clinical Pharmacology - Tập 48 Số 3 - Trang 382-387 - 1999
Abdul Manap1, Caroline Wright1, A. Gregory2, Amin Rostami‐Hodjegan2, Meller3, Kelm3, Lennard2, Anne M. Tucker2, Morice1
1Pulmonary Medicine, Division of Clinical Sciences, University of Sheffield, Northern General Hospital, Sheffield, S5 7AU, UK
2Section of Molecular Pharmacology and Pharmacogenetics, Division of Clinical Sciences, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK
3OTC‐HCTD, The Procter and Gamble Company, 8700 Mason‐Montgomery Road, Mason, OH 45040, USA

Tóm tắt

Aims To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model. Methods Twenty‐two healthy extensive metaboliser phenotypes for CYP2D6 were studied according to a double‐blind, randomised cross‐over design after administration of: (1) Placebo antitussive preceded at 1 h by placebo inhibitor; (2) 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30); (3) 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60); (4) 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30). Cough frequency following inhalation of 10% citric acid was measured at baseline and at intervals up to 12 h. Plasma concentrations of DEX and its metabolites were measured up to 96 h by h.p.l.c. Results Inhibition of CYP2D6 by quinidine caused a significant increase in the mean ratio of DEX to dextrorphan (DEX:DOR) plasma AUC(96) (0.04 vs 1.81, P<0.001). The mean (±s.d.) decrements in cough frequency below baseline over 12 h (AUEC) were: 8% (11), 17% (14.5), 25% (16.2) and 25% (16.9) for placebo, DEX30, DEX60 and QDEX30 treatments, respectively. Statistically significant differences in antitussive effect were detected for the contrasts between DEX60/placebo (P<0.001; 95% CI of difference +80, +327) and QDEX30/placebo (P<0.001, +88, +336), but not for DEX30/placebo, DEX30/DEX60 or DEX30/QDEX30 (P=0.071, −7, +241; P=0.254, −37, +211; P=0.187, −29, +219, respectively). Conclusions A significant antitussive effect was demonstrated after 60 mg dextromethorphan and 30 mg dextromethorphan preceded by 50 mg quinidine using an induced cough model. However, although the study was powered to detect a 10% difference in cough response, the observed differences for other contrasts were less than 10%, such that it was possible only to imply a dose effect (30 vs 60 mg) in the antitussive activity of DEX and enhancement of this effect by CYP2D6 inhibition.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM195307232490402

10.1177/030006058301100206

Cass LJ, 1956, Quantitative comparison of cough suppressant effects of Romilar and other antitussive agents., J Lab Clin Med, 48, 879

Aylward M, 1984, Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects., Eur J Resp Dis, 65, 283

10.1006/pulp.1996.0039

10.1111/j.1365-2125.1995.tb04446.x

10.1159/000195303

10.1016/0041-008X(80)90218-5

10.1016/0006-2952(94)90237-2

Von Moltke LL, 1998, Revaluation of the specificity of dextromethorphan as an index substrate., Clin Pharmacol Ther, 63, 227

10.1111/j.2042-7158.1998.tb06914.x

10.1002/(SICI)1099-081X(199704)18:3<227::AID-BDD18>3.0.CO;2-L

10.1097/00008571-199308000-00004

10.1111/j.1365-2125.1990.tb03639.x

10.1111/j.1365-2125.1986.tb05250.x

10.1038/clpt.1992.77

10.1016/S0009-9236(96)90056-9

10.1016/S0021-9673(00)89216-X

ArmitageP&BerryGThe planning of statistical investigations. InStatistical MethodsIn Medical Research 2nd edn Blackwell Scientific Publications 1987: p. 182

10.1097/00007691-199001000-00018

10.1097/00008571-199712000-00003

10.1038/clpt.1989.36

10.1111/j.1365-2125.1990.tb03653.x

10.1006/pulp.1996.0036

Braga PC, 1994, Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs., Drugs Exp Clin Res, 20, 199

Thông tin
Thông tin xuất bản

British Journal of Clinical Pharmacology

Tập 48 Số 3

382-387

Thông tin tác giả